24 May 2013
Keywords: roche, xeloda, replace, 5-fu/lv, landmark, x-act, study
Article | 11 July 2005
The landmark X-ACT study (Xeloda in Adjuvant Colon Cancer Therapy) shows that Roche's Xeloda (capecitabine) is an effective alternative to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 July 2005
4 July 2005
© 2013 thepharmaletter.com